GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Construction In Progress

ALMS (Alumis) Construction In Progress : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Construction In Progress?

Alumis's annual construction in progress declined from Dec. 2022 ($0.58 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Alumis Construction In Progress Historical Data

The historical data trend for Alumis's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Construction In Progress Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24
Construction In Progress
0.58 - -

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Construction In Progress Get a 7-Day Free Trial Premium Member Only - - - - -

Alumis Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Alumis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Construction In Progress
Comparable Companies
THRD CADL CDTX HUMA FHTX PLX PRME NVCT DSGN NGNE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Website
https://www.alumis.com
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.